DE60317365D1 - Substituierte 4-alkoxyoxazol derivate als ppar agonisten - Google Patents
Substituierte 4-alkoxyoxazol derivate als ppar agonistenInfo
- Publication number
- DE60317365D1 DE60317365D1 DE60317365T DE60317365T DE60317365D1 DE 60317365 D1 DE60317365 D1 DE 60317365D1 DE 60317365 T DE60317365 T DE 60317365T DE 60317365 T DE60317365 T DE 60317365T DE 60317365 D1 DE60317365 D1 DE 60317365D1
- Authority
- DE
- Germany
- Prior art keywords
- alkoxyoxazole
- derivatives
- substituted
- ppar agonists
- ppar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02025001 | 2002-11-08 | ||
EP02025001 | 2002-11-08 | ||
PCT/EP2003/012189 WO2004041275A1 (en) | 2002-11-08 | 2003-10-31 | Substituted 4-alkoxyoxazol derivatives as ppar agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60317365D1 true DE60317365D1 (de) | 2007-12-20 |
DE60317365T2 DE60317365T2 (de) | 2008-08-21 |
Family
ID=32309325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60317365T Expired - Lifetime DE60317365T2 (de) | 2002-11-08 | 2003-10-31 | Substituierte 4-alkoxyoxazol derivate als ppar agonisten |
Country Status (16)
Country | Link |
---|---|
US (1) | US7109225B2 (de) |
EP (1) | EP1572203B1 (de) |
JP (1) | JP4551222B2 (de) |
KR (1) | KR100699614B1 (de) |
CN (1) | CN1711084B (de) |
AR (1) | AR041997A1 (de) |
AT (1) | ATE377419T1 (de) |
AU (1) | AU2003276234B2 (de) |
BR (1) | BR0316091A (de) |
CA (1) | CA2503117C (de) |
DE (1) | DE60317365T2 (de) |
ES (1) | ES2295692T3 (de) |
MX (1) | MXPA05004743A (de) |
PL (1) | PL210871B1 (de) |
RU (1) | RU2312106C2 (de) |
WO (1) | WO2004041275A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
PT1680443E (pt) | 2003-11-05 | 2013-12-11 | Harvard College | Péptidos alfa-helicoidais estabilizados e suas utilizações |
AU2008210434C8 (en) | 2007-01-31 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
BRPI0809366B8 (pt) * | 2007-03-28 | 2021-05-25 | Harvard College | polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica |
EP2356139A4 (de) | 2008-07-23 | 2013-01-09 | Harvard College | Ligieren zusammengehefteter polypeptide |
EP2342221B1 (de) | 2008-09-22 | 2018-11-07 | Aileron Therapeutics, Inc. | Verfahren zur herstellung aufgereinigter polypeptidzusammensetzungen |
US20100216827A1 (en) * | 2008-10-21 | 2010-08-26 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
WO2010083347A2 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8859723B2 (en) | 2010-08-13 | 2014-10-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8957026B2 (en) | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
ES2861268T3 (es) | 2011-09-20 | 2021-10-06 | Basf Se | Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso |
CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US8927500B2 (en) | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
HUE054444T2 (hu) | 2012-09-26 | 2021-09-28 | Harvard College | Prolinnal lezárt kapcsos peptidek és felhasználásuk |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
KR20150131244A (ko) | 2013-03-13 | 2015-11-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스테이플드 및 스티치드 폴리펩티드 및 그의 용도 |
CN105492460A (zh) | 2013-06-14 | 2016-04-13 | 哈佛大学的校长及成员们 | 稳定化多肽胰岛素受体调控剂 |
CN106573032B (zh) | 2014-05-21 | 2022-03-18 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP3347372A4 (de) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | Peptidomimetische makrocyclen als modulatoren von mcl-1 |
WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
GB9712866D0 (en) * | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
EP1067109B1 (de) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
US7348426B1 (en) * | 1999-04-28 | 2008-03-25 | Dr. Reddy's Laboraties Limited | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
JP2001261612A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
PL360744A1 (en) * | 2000-08-23 | 2004-09-20 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
ES2295200T3 (es) * | 2000-08-23 | 2008-04-16 | Eli Lilly And Company | Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar. |
EP1313715B1 (de) * | 2000-08-23 | 2007-08-01 | Eli Lilly And Company | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten |
-
2003
- 2003-10-31 WO PCT/EP2003/012189 patent/WO2004041275A1/en active IP Right Grant
- 2003-10-31 PL PL376920A patent/PL210871B1/pl not_active IP Right Cessation
- 2003-10-31 DE DE60317365T patent/DE60317365T2/de not_active Expired - Lifetime
- 2003-10-31 CA CA2503117A patent/CA2503117C/en not_active Expired - Fee Related
- 2003-10-31 RU RU2005117964/04A patent/RU2312106C2/ru not_active IP Right Cessation
- 2003-10-31 AU AU2003276234A patent/AU2003276234B2/en not_active Ceased
- 2003-10-31 AT AT03810427T patent/ATE377419T1/de active
- 2003-10-31 KR KR1020057008035A patent/KR100699614B1/ko not_active IP Right Cessation
- 2003-10-31 MX MXPA05004743A patent/MXPA05004743A/es active IP Right Grant
- 2003-10-31 EP EP03810427A patent/EP1572203B1/de not_active Expired - Lifetime
- 2003-10-31 BR BR0316091-2A patent/BR0316091A/pt not_active IP Right Cessation
- 2003-10-31 JP JP2004548844A patent/JP4551222B2/ja not_active Expired - Fee Related
- 2003-10-31 CN CN2003801028413A patent/CN1711084B/zh not_active Expired - Fee Related
- 2003-10-31 ES ES03810427T patent/ES2295692T3/es not_active Expired - Lifetime
- 2003-11-04 US US10/700,417 patent/US7109225B2/en not_active Expired - Fee Related
- 2003-11-06 AR ARP030104080A patent/AR041997A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2503117C (en) | 2010-12-21 |
CA2503117A1 (en) | 2004-05-21 |
ATE377419T1 (de) | 2007-11-15 |
KR100699614B1 (ko) | 2007-03-23 |
RU2312106C2 (ru) | 2007-12-10 |
EP1572203B1 (de) | 2007-11-07 |
US20040157898A1 (en) | 2004-08-12 |
DE60317365T2 (de) | 2008-08-21 |
PL376920A1 (pl) | 2006-01-09 |
WO2004041275A1 (en) | 2004-05-21 |
US7109225B2 (en) | 2006-09-19 |
ES2295692T3 (es) | 2008-04-16 |
MXPA05004743A (es) | 2005-08-03 |
CN1711084B (zh) | 2010-04-28 |
JP4551222B2 (ja) | 2010-09-22 |
PL210871B1 (pl) | 2012-03-30 |
JP2006508097A (ja) | 2006-03-09 |
RU2005117964A (ru) | 2006-03-27 |
BR0316091A (pt) | 2005-09-27 |
CN1711084A (zh) | 2005-12-21 |
AR041997A1 (es) | 2005-06-08 |
EP1572203A1 (de) | 2005-09-14 |
AU2003276234A1 (en) | 2004-06-07 |
KR20050084958A (ko) | 2005-08-29 |
AU2003276234B2 (en) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60317365D1 (de) | Substituierte 4-alkoxyoxazol derivate als ppar agonisten | |
ATE416171T1 (de) | 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren | |
IS8439A (is) | Nýjar kínólín afleiður | |
IS7667A (is) | Nýjar bensimídazólafleiður | |
DE60308670D1 (de) | Substituierte indole als alpha-1 agonisten | |
DE602004015498D1 (de) | Substituierte pyrazole als ppar-agonisten | |
DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
DE60308850D1 (de) | Pyridinoylpiperidine als 5-ht1f agonisten | |
ATE392206T1 (de) | Indolderivate als beta-2 agonisten | |
IS7607A (is) | Ný útskipt indól | |
DK1531673T3 (da) | Hidtil ukendt 2-pyridylethylbenzamidderivat | |
IS8180A (is) | Nýjar besímídasólafleiður | |
ATE392897T1 (de) | Chinolinderivate als npy antagonisten | |
ATE426599T1 (de) | Thiazolylpiperidin derivate als mtp inhibitoren | |
DE602005015204D1 (de) | Oxadiazolonderivate als ppar-delta-agonisten | |
DE602004029363D1 (de) | N-alkynyl-2-(substituierte aryloxy)alkylthioamide derivate als fungizide | |
DE602004024770D1 (de) | Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
ATE386518T1 (de) | Benzimidazolderivate | |
FR2845095B1 (fr) | Piece coulissante | |
ATE308325T1 (de) | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren | |
DE602004009796D1 (de) | Imidazolderivate als glutamatrezeptorantagonisten | |
DE602004004295D1 (de) | 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel | |
ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
DE60328233D1 (de) | Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |